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A B S T R A C T
Purpose
Chemotherapy with alternating vincristine-doxorubicin-cyclophosphamide and ifosfamide-etoposide cycles
and primary tumor treatment with surgery and/or radiation therapy constitute the usual approach to
localized Ewing sarcoma in North America. We tested whether chemotherapy intensification through
interval compression could improve outcome.
Patients and Methods
This was a prospective, randomized controlled trial for patients younger than 50 years old with
newly diagnosed localized extradural Ewing sarcoma. Patients assigned to standard and intensi-
fied treatment were to begin chemotherapy cycles every 21 and 14 days, respectively, provided
an absolute neutrophil count greater than 750  106/L and a platelet count greater than 75  109/L.
Patients received vincristine (2 mg/m2), doxorubicin (75 mg/m2), and cyclophosphamide (1.2 g/m2)
alternating with ifosfamide (9 g/m2) and etoposide (500 mg/m2) for 14 cycles, with filgrastim (5
mg/kg per day; maximum, 300 mg) between cycles. Primary tumor treatment (surgery, radiation,
or both) was to begin at week 13 (after four cycles in the standard arm and six cycles in the
intensified arm). The primary end point was event-free survival (EFS). The study is registered at
ClinicalTrials.gov (identifier: NCT00006734).
Results
Five hundred eighty-seven patients were enrolled and randomly assigned, and 568 patients were
eligible, with 284 patients in each regimen. For all cycles, the median cycle interval for standard
treatment was 21 days (mean, 22.45 days); for intensified treatment, the median interval was 15
days (mean, 17.29 days). EFS at a median of 5 years was 65% in the standard arm and 73% in the
intensified arm (P  .048). The toxicity of the regimens was similar.
Conclusion
For localized Ewing sarcoma, chemotherapy administered every 2 weeks is more effective than
chemotherapy administered every 3 weeks, with no increase in toxicity.
J Clin Oncol 30:4148-4154. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Since the first Intergroup Ewing’s Sarcoma Study
(IESS) in the 1970s, it has been clear that chemother-
apy, with primary tumor treatment involving sur-
gery or radiotherapy, is indispensable for successful
treatment of Ewing sarcoma and related tumors.1
IESS-I established the importance of doxorubicin in
Ewing sarcoma chemotherapy, whereas IESS-II and
subsequent meta-analyses showed the importance
of doxorubicin dose-intensity.2-4 The North Amer-
ican intergroup Ewing sarcoma study INT-0091
demonstrated that a regimen of alternating
vincristine-doxorubicin-cyclophosphamide (VDC)
and ifosfamide-etoposide (IE) was superior to VDC,
with approximately 70% of patients with localized
tumors apparently cured.5
In the absence of new effective agents for Ewing
sarcoma, the Children’s Oncology Group focused
on improving outcome by increasing chemotherapy
dose-intensity. There are two ways to increase
the dose-intensity of chemotherapy, increasing the
doses given or decreasing the interval between doses.
The Pediatric Oncology Group and Children’s Can-
cer Group explored the first method in the INT-
0154 study, whose standard arm used VDC/IE in
standard doses for 17 cycles administered every 3
weeks, whereas the experimental arm used 11 higher
dose cycles administered every 3 weeks to complete
treatment with the same total doses. The results
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showed no improvement in event-free survival (EFS) or overall sur-
vival but higher toxicity in the dose-intense arm.6
A pilot study demonstrated the feasibility of dose intensification
by interval compression (sometimes termed increased dose density)
using filgrastim between chemotherapy cycles. Induction cycles had a
median duration of 16 days, and although cycle duration increased
with continuing therapy, the median duration was still 21 days or less
at cycle 11. Toxicity was well within the range usually associated with
Ewing sarcoma therapy.7 This study was designed to test whether dose
intensification by interval compression could improve the prognosis
of patients with localized Ewing sarcoma.
PATIENTS AND METHODS
Protocol AEWS0031 was available to member institutions of the Children’s
Oncology Group from May 2001 to August 2005. The study was also open to
members of the Southwest Oncology Group from July 2003 to August 2005,
but no eligible patients were enrolled.
Patient Eligibility
To be eligible, patients had to have a new diagnosis of Ewing sarcoma,
peripheral neuroectodermal tumor, primitive neuroectodermal tumor, or
Askin’s tumor. The primary site could be bone or soft tissue, but not intradural
soft tissues. Patients could have no evidence of metastatic disease on a radio-
nuclide bone scan, chest computed tomography scan, and bilateral bone
marrow aspirates and biopsies. We considered one pulmonary or pleural
nodule greater than 1 cm in diameter or more than one nodule greater than 0.5
cm in diameter on chest computed tomography scan to be evidence of metas-
tasis. Patients with chest wall tumors and ipsilateral pleural effusions or
pleural-based secondary nodules were considered to have localized disease, as
were patients with clinically or pathologically involved regional lymph nodes.
We excluded patients with a history of any other malignancy (except skin
cancer not treated with chemotherapy, radiation, or immunotherapy); preg-
nant or lactating patients; and patients with inadequate heart, renal, or liver
function. Chemotherapy had to begin within 30 days of initial biopsy. All
patients ( age 18 years) or their parents or guardians signed written informed
consent for participation. The Children’s Oncology Group does not ascertain
potential patients except through study enrollment, and the computerized
remote enrollment system rejected patients whose entered data did not meet
these requirements.
Pathologically, the tumor had to have a light microscopic appearance (using
hematoxylin and eosin) consistent with a Ewing family tumor with no immuno-
histochemical or ultrastructural evidence indicating otherwise. Immunohisto-
chemical use of a panel of muscle-specific antibodies and antibodies to lymphoid
antigens was recommended; CD99 positivity and evidence of an appropriate EWS
rearrangementbyreversetranscriptasepolymerasechainreactionorfluorescentin
situ hybridization were considered supportive. At least one study pathologist
(P.S.D. or B.R.P.) reviewed all diagnostic slides and test results.
Study Design
Patients were randomly assigned to the control regimen A or the exper-
imental regimen B (Fig 1). Patients assigned to regimen A received chemother-
apy every 21 days, whereas patients assigned to regimen B received
chemotherapy every 14 days or as soon as blood count recovery permitted.
Both regimens used 14 alternating cycles of VDC/IE with filgrastim, with
identical per-cycle and total doses. Treatment also included primary tumor
treatment with surgery, radiation, or a combination. Detailed treatment
schedules for patients receiving various primary tumor treatment modalities
are listed in Appendix Table A1 (online only).
Filgrastim administration was to stop when the absolute neutrophil
count (ANC) was at least 750106/L and the platelet count at least 75109/L.
Once ANC and platelet count criteria were met, chemotherapy was to proceed
24 hours after the last filgrastim dose regardless of whether the ANC decreased
after discontinuation of filgrastim. With the chemotherapy cycle beginning on
day 0, patients on regimen A were to have blood counts checked on days 7, 14,
and 21; patients on regimen B were to have counts checked on days 7 and 14
and then every Monday, Wednesday, and Friday until blood count criteria
were met.
Primary tumor treatment began at treatment week 13, after four cycles of
chemotherapy in regimen A and six cycles in regimen B. It could consist of
complete surgical excision with clear margins, surgery with radiation therapy
for close or positive margins, or radiation therapy alone. Minimal adequate
bony margins to avoid radiation therapy were defined as 1 cm (2 to 5 cm
recommended), and minimal soft tissue margins were defined as 5 mm in
muscle or fat or 2 mm with fascial planes. Radiation therapy doses were 45 Gy
to the initial volume and 55.8 Gy to the final volume of unresected tumors, 50.4
Gy to extraosseous tumors with a complete response to chemotherapy, 45 Gy
to vertebral bony primary tumors, and 45 Gy to pathologically involved lymph
node areas. Preoperative radiotherapy was permitted with a dose of 45 Gy.
Patients with chest wall primary tumors and ipsilateral pleural-based tumor
nodules received 15 Gy to the hemithorax (12 Gy for patients  6 years old)
and 36.6 Gy to any unresected gross pleural tumor. All radiation therapy was to
be given in 1.8-Gy fractions.
Statistical Design
Institutional investigators enrolled patients using a Web-based interface.
At enrollment, patients were stratified into groups according to age ( 17 years
v  18 years) and primary tumor site (nonpelvic v pelvic). After eligibility was
confirmed, the randomized treatment assignment was generated by computer
and reported to the investigator. Assignments were done in permuted blocks
of size four.8
Enrollment of 4.5 years with an additional year of follow-up provided for
the detection of a hazard ratio (HR) of 0.64 in the failure rate with a probability
of 0.80 when using a two-sided test with size P  .05. Four instances of interim
monitoring were planned. The final analysis was planned for 5.5 years after the
first patient was enrolled. Data current through March 2009 (7.8 years after
first enrollment) were used in this analysis.
The primary study end point was EFS, defined as the time from entry onto
the study until the occurrence of an adverse event (disease progression, second
malignant neoplasm, or death) or until the last contact with the patient, whichever
camefirst.Diseaseprogressionwasfurthersubclassifiedas localprogression(atthe
primary site only), systemic progression (at a site other than the primary site), or
local plus systemic progression (at the primary site and another site).
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Fig 1. Design of the study. Regimen A was the control regimen, and regimen
B was the experimental (intensified) regimen. Cycles of vincristine-doxorubicin-
cyclophosphamide alternated with cycles of ifosfamide-etoposide. CPM, cyclo-
phosphamide (1,200 mg/m2 on day 1 of each cycle); Dox, doxorubicin (37.5
mg/m2 on days 1 and 2 of each cycle; cumulative dose, 375 mg/m2 for all
patients); ETOP, etoposide (100 mg/m2 on days 1 through 5 of each cycle); IFOS,
ifosfamide (1,800 mg/m2 on days 1 through 5 of each cycle); VCR, vincristine (1.5
mg/m2 [maximum, 2 mg] on day 1 of each cycle); Q2W, every 2 weeks; Q3W,
every 3 weeks.
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EFS was estimated by the Kaplan-Meier method.9 The log-rank sta-
tistic was used to compare the risk of an adverse event between patient
groups.10 Patients’ randomized treatment assignments were used in all
comparisons involving regimens. The HRs and significance associated
with patient characteristics at enrollment were assessed in a proportional
hazards regression model in which the characteristic of interest was the
only component.10 CIs for HRs were derived from that model. The cumu-
lative incidence of each type of event was calculated according to Prentice
et al.11 Cumulative incidence was compared across regimens using the
method of Fine and Gray.12 The hypothesis of equal frequency of qualita-
tive characteristics across groups defined by treatment assignment was
assessed using the exact conditional test of proportions.13
The number of days required to complete a cycle of therapy and the
number of days hospitalized during each cycle were compared across ran-
domly assigned regimens using the Wilcoxon signed rank test. The relative
average intensity of the regimens was estimated as the mean days for standard
timing cycles divided by that for intensified cycles. STATA version 12 (STATA,
College Station, TX) was used for all analyses of censored survival data and
cumulative incidence; SAS version 9.2 (SAS Institute, Cary, NC) was used for
all other statistical calculations.
RESULTS
Patient Accrual and Random Assignment
Five hundred eighty-seven patients were enrolled onto the study
(Fig 2) from 152 institutions. Nineteen patients were deemed ineligi-
ble, 12 because of a wrong diagnosis (not Ewing sarcoma), four be-
cause of metastases at diagnosis, two because of treatment before
enrollment or random assignment, and one because treatment began
more than 30 days after biopsy. Thus, 568 patients were eligible, with
284 patients assigned to each regimen (Table 1). At the time of analy-
sis, 398 patients had not experienced an EFS event (median follow-up,
61 months; range, 7 to 94 months).
Chemotherapy Intensification
We analyzed 2,897 cycles in regimen A and 2,862 cycles in regi-
men B. For all patients and all phases, the mean cycle durations were
22.45  4.87 days and 17.29  5.40 days in regimens A and B,
respectively (P  .001; Table 2). Patients age 17 years and younger had
almost identical cycle durations as older patients.
Because we observed in the pilot study that radiation therapy led
to prolongation of continuation chemotherapy cycles,7 we analyzed
them separately for patients treated with and without radiation ther-
apy. Patients on regimen B treated with radiation had mean and
median continuation cycle durations that were approximately 1.5
days longer than patients who were not treated with radiation, but the
durations were still significantly shorter than in regimen A. Even
patients with irradiated pelvic tumors had shorter cycle durations than
their nonirradiated counterparts.
Local Control Measures
We were unable to determine the method of primary tumor
treatment in 18 patients, five patients had events before local control,
and seven patients had no local control measures reported. Of the
remaining patients, 274 had surgery only, 115 had radiation only, and
149 had both. The local control measures differed between the two
regimens, with more patients treated on the standard arm receiving
surgery and radiation and more patients on the intensive regimen
receiving radiation alone (Fig 2), but the differences did not achieve
statistical significance (P  .101 by Fisher’s exact test).
Treatment Efficacy
At 5 years, the EFS rate on regimen B was 73%, compared with
65% on regimen A (P  .048; Fig 3A); the HR associated with regimen
B was 0.74 (95% CI, 0.54 to 0.99). Overall survival was 83% for
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Regimen A
(n = 284)
Regimen B
(n = 284)
Type of LC
  SX only (n = 138)
  RT only (n = 49)
  SX + RT (n = 86)
  None (n = 4)
Type of LC
  SX only (n = 136)
  RT only (n = 66)
  SX + RT (n = 63)
  None (n = 3)
LC modality
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(n = 5)
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(n = 1)
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(n = 9)
Relapse (n = 66)
  Local only (n = 20)
  Distant only (n = 39)
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(n = 209)
Death
(n = 2)
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(n = 7)
Fig 2. CONSORT diagram. Patients who experienced a relapse, second malignant neoplasm (SMN), or death before the last contact date were counted as having an
event. LC, local control; RT, radiation therapy; SX, surgery.
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regimen B and 77% for regimen A (P  .056; Fig 3B); the HR associ-
ated with regimen B was 0.69 (95% CI, 0.47 to 1.0).
Interval-compressed therapy had no apparent effect on local
recurrence (5-year cumulative incidence: 0.080 for regimen A; 95%
CI, 0.052 to 0.12; 0.072 for regimen B; 95% CI, 0.045 to 0.11; P  .74)
but was related to distant and combined local and distant relapse
(5-year cumulative incidence: 0.23 for regimen A; 95% CI, 0.19 to
0.30; 0.16 for regimen B; 95% CI, 0.13 to 0.23; P  .058; Fig 2).11
Combining the treatment arms, older patients and patients
with pelvic primary tumors were at relative disadvantages
(P  .001 for EFS and survival; Figs 3C and 3D). In particular,
outcome was considerably worse for patients age 18 years and older
Table 1. Patient Demographics and Clinical Characteristics
Demographic or Clinical Characteristic
Standard Timing: Regimen A
Intensive Timing:
Regimen B All Patients
No. of Patients % No. of Patients % No. of Patients %
Age at diagnosis, years
 9 88 31 74 26 162 29
10-17 165 58 174 61 339 60
18 31 11 36 13 67 12
Median 12 13 12
Range 0-33 0-45 0-45
Sex
Male 154 54 154 54 308 54
Female 130 46 130 46 260 46
Race
White 252 89 250 88 502 88
African American 8 3 6 2 14 2
American Indian 3 1 2 1 5 1
Asian 8 3 8 3 16 3
Pacific Islander 1 0.003 0 0 1 0.001
Not reported 12 4 18 6 30 5
Ethnicity
Not Hispanic 258 91 250 88 508 89
Hispanic 21 7 29 10 50 9
Not reported 5 2 5 2 10 3
Primary site (bone unless otherwise specified)
Skull 18 6 13 5 31 5
Spine 14 5 30 11 44 8
Ribs 34 12 25 9 59 10
Sternum, scapula, or clavicle 15 5 15 5 30 5
Humerus 13 5 12 4 25 4
Radius, ulna, or bone of the hand 7 2 8 3 15 3
Pelvis 47 17 43 15 90 16
Femur 33 12 28 10 61 11
Tibia, fibula, patella, or bone of the foot 51 18 43 15 94 17
Soft tissue 52 18 67 24 119 21
Table 2. Dose Intensification
Group
Cycle Duration in Regimen A:
Standard Timing (days)
Cycle Duration in Regimen B:
Intensified Timing (days)
PMean SD Median Mean SD Median
All 22.45 4.87 21 17.29 5.40 15  .001
Induction 21.65 2.64 21 16.23 4.46 15  .001
Continuation 22.84 5.62 21 18.17 5.74 16  .001
Continuation with RT 23.00 5.18 21 19.2 6.12 18  .001
Continuation without RT 22.73 5.79 21 17.71 5.45 16  .001
Pelvic with RT 24.18 6.79 21 19.61 5.76 19  .001
Pelvic without RT 22.39 5.37 21 17.36 5.93 15  .001
All age 0-17 years 22.48 4.93 21 17.31 5.30 15  .001
All age  18 years 22.21 4.53 21 17.16 6.20 15  .001
Abbreviations: RT, radiation therapy; SD, standard deviation.
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than for patients younger than 18 years (EFS at 5 years: 47% v 72%,
respectively; P  .001).
Events Other Than Relapse
There was one toxic death of a patient on regimen B who devel-
oped colitis and sepsis while neutropenic. One patient died of infec-
tion 40 months after enrollment, not associated with protocol therapy.
One patient died in remission of a narcotic overdose 28 months
after diagnosis.
Sixteen patients developed second malignancies, nine on regi-
men A and seven on regimen B (P .62). There were 11 acute myeloid
leukemias (five on regimen A and six on regimen B), three osteosar-
comas in radiation fields (two on regimen A and one on regimen B),
and two lymphomas (both on regimen A).
Toxicity
Table 3 lists the grade 3 and 4 toxicities that were reported in at
least 1% of the chemotherapy cycles in either regimen and all toxicities
involving fever or infection. No important differences were observed
between the regimens.
Because grade 3 or 4 toxicities (especially infections and febrile neu-
tropenia) usually require hospitalization, we compared hospital days in
the two regimens. Patients receiving regimen A had a mean of 5.0  4.25
hospital days per cycle (median, 4 days), whereas patients on regimen B
had a mean of 5.1  4.26 hospital days (median, 4 days; P  .43).
DISCUSSION
These results demonstrate that reducing the interval between chem-
otherapy cycles from 3 weeks to 2 weeks using filgrastim improves
the efficacy of treatment in patients with localized Ewing sarcoma
family tumors. The improvement in EFS, from 65% at 5 years in
the control arm to 73% in the experimental arm, represents a 22%
decrease in the risk of recurrence. This was achieved with no
increase in toxicity. The superiority of the intensified arm in overall
survival just misses conventional statistical significance (P  .056);
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Fig 3. Kaplan-Meier plots of treatment outcome. (A) Event-free survival (EFS) according to the assigned treatment regimen. (B) Overall survival (OS) by regimen. (C)
EFS and (D) OS, respectively, for the four strata, pooling the treatment regimens.
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although relapsed Ewing sarcoma is rarely cured, patients often
survive from several months to a few years after relapse, causing
survival to lag behind EFS.
The improvement in prognosis seen with dose intensification by
interval compression in Ewing sarcoma contrasts with the lack of im-
provement in the preceding pediatric intergroup study, in which the
experimental regimen had fewer cycles with higher doses of alkylating
agents ineach,maintainingthetraditional3-weekintervalbetweencycles.
The experimental arm had increased toxicity but no greater efficacy.14
Two possible explanations for the difference are that our study increased
the dose-intensity of all five chemotherapeutic agents used, rather than
just the alkylating agents, and that a shorter interval between chemother-
apy cycles provides greater efficacy.
The use of filgrastim in our study was critical. Investigators at the
National Cancer Institute attempted interval compression in pediatric
patients with sarcoma using sargramostim (granulocyte-macrophage
colony-stimulating factor), rather than filgrastim, in a randomized
controlled trial using a similar chemotherapy regimen. Sargramostim
accelerated neutrophil recovery but seemed to delay platelet recovery,
so that there was no acceleration of therapy or increased dose-
intensity. Apart from more documented bacteremia in the sargramos-
tim arm, there were no important differences in toxicity, EFS, or
overall survival between the two arms.15
Our interval compression strategy follows Norton’s dose density
model16 in maintaining doses while decreasing the intervals between
them, thus also increasing dose-intensity. Dose-dense chemotherapy
has had mixed results in other malignancies. In a randomized
trial in pediatric acute myeloid leukemia, accelerated induction chem-
otherapy markedly improved EFS and disease-free survival, and the
advantage persisted in all three postremission treatment arms.17 In
breast cancer, the C9741 study demonstrated that chemotherapy ad-
ministered every 2 weeks was superior to chemotherapy administered
every 3 weeks, with less toxicity, using both concurrent and sequential
doxorubicin-cyclophosphamide-paclitaxel regimens.18
The European Osteosarcoma Intergroup study compared doxoru-
bicin and cisplatin administered every 2 weeks versus every 3 weeks in
patients with new diagnoses of localized osteosarcoma; the acceleration
produced more good histologic responses but had no effect on EFS or
overall survival.19 In extensive small-cell lung cancer, accelerated chemo-
therapy similarly improved the response rate without affecting median
survival or 2-year survival.20 The Children’s Oncology Group recently
completed a single-arm prospective study testing accelerated chemother-
apy in patients with high-risk rhabdomyosarcoma, and results are pend-
ing. Some other dose-dense approaches have reduced doses with
decreased intervals, maintaining (rather than increasing) dose-intensity.
This was the third randomized North American study of Ewing
sarcoma sharing a similar regimen, with alternating VDC and IE
chemotherapy at standard doses administered every 3 weeks. The
relevant arms of INT-0091 and INT-0154 had 5-year EFS rates of 69%
and 70%, respectively, not significantly different from the 65% EFS
rate in the current study (P  .33 by log-rank test); overall survival is
also similar (P  .44). Although comparisons across studies are
tempting, the reason we go to the trouble and expense of randomized
controlled trials is that using historical controls (either formally or
casually) is often misleading.21,22
Recently, Morales-Arias et al23 reported expression of the granulo-
cyte colony-stimulating factor (G-CSF) receptor and G-CSF in four of six
Ewing sarcoma cell lines tested, as well as in each of 83 clinical Ewing
sarcoma specimens. Although added G-CSF had no effect on growth of
one of the cell lines in vitro, it more than doubled the volume of mouse
xenografts compared with saline-treated controls, leading the authors to
warn that G-CSF treatment may stimulate Ewing sarcoma growth in
patients.23 However, this is not apparent from the available clinical litera-
ture. Filgrastim received US Food and Drug Administration approval in
February 1991, roughly halfway through the accrual to the INT-0091
Ewing sarcoma study,24 and all patients received it in the INT-0154 study
and AEWS0031. Comparing the comparable arms of the three studies
(the experimental arm of INT-0091 and the control arms of the more
recent trials), one finds almost identical EFS and overall survival, making
an adverse effect of G-CSF on outcome unlikely.
Pegylated filgrastim (pegfilgrastim) came to market shortly before
this study opened. Although it offers the advantage of a single injection
rather than a series of 10 to 14 daily injections, we forbade its use because
ofa lackofexperiencewitheither intervalcompressionorchildren.Itnow
seems that pegfilgrastim also permits interval compression with similar
effectiveness to filgrastim in children.25
Interval-compressed chemotherapy with VDC/IE and filgrastim
is more effective in localized Ewing sarcoma than the same chemo-
therapy given at standard 3-week intervals, with no increase in toxic-
ity. This could have implications for treatment of other childhood
malignancies and other sarcomas in all ages.
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